SGLT2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A South Australian Clinical Case Series and Australian Spontaneous Adverse Event Notifications

Clinical cases were collected from South Australia between December 2015 and March 2017. The audit was approved by the Royal Adelaide Hospital Human Research Ethics Committee (HREC reference no. HREC/17/RAH/185).

The Therapeutic Goods Administration (TGA) of the Australian Government Department of Health was contacted, and a search of the Database of Adverse Event Notifications (medicines) for all reports of SGLT2 inhibitor–associated DKA was requested up until April 2017 using the search terms ketoacidosis, diabetic ketoacidosis, and generic and brand drug names. Full case line listings for each notification were provided by the TGA.